BACKGROUND: Hematoma expansion after acute intracerebral hemorrhage occurs most frequently in patients presenting within 3 h of symptom onset. However, the majority of patients present outside this window or with an unknown onset time. We investigated the prevalence of hematoma expansion in these patients and assessed the accuracy of the CT angiography (CTA) spot sign for identifying risk of hematoma expansion. METHODS: We analyzed 391 consecutive patients undergoing CTA and a followup CT. CTA spot sign readings were performed by two experienced readers and hematoma expansion was assessed by means of semi-automated software. RESULTS: Hematoma expansion occurred in 18 % of patients. When stratified by time from symptom onset to initial CT, hematoma expansion rates were: 39 % within 3 h; 11 % between 3 and 6 h, 11 % beyond 6 h (but with known onset), and 20 % in patients with unknown symptom onset. Of patients who developed hematoma expansion, only 38 % presented within 3 h. The accuracy of the spot sign in predicting hematoma expansion was 0.67 for patients presenting within 3 h, 0.83 between 3 and 6 h, 0.88 after 6 h, and 0.76 for patients presenting with an unknown onset time. CONCLUSIONS: A substantial number of patients destined to suffer from hematoma expansion present either late or with an unknown symptom onset time. The CTA spot sign accurately identifies patients destined to expand regardless of time from symptom onset, and may therefore open a path to offer clinical trials and novel therapies to the many patients who do not present acutely.
BACKGROUND:Hematoma expansion after acute intracerebral hemorrhage occurs most frequently in patients presenting within 3 h of symptom onset. However, the majority of patients present outside this window or with an unknown onset time. We investigated the prevalence of hematoma expansion in these patients and assessed the accuracy of the CT angiography (CTA) spot sign for identifying risk of hematoma expansion. METHODS: We analyzed 391 consecutive patients undergoing CTA and a followup CT. CTA spot sign readings were performed by two experienced readers and hematoma expansion was assessed by means of semi-automated software. RESULTS:Hematoma expansion occurred in 18 % of patients. When stratified by time from symptom onset to initial CT, hematoma expansion rates were: 39 % within 3 h; 11 % between 3 and 6 h, 11 % beyond 6 h (but with known onset), and 20 % in patients with unknown symptom onset. Of patients who developed hematoma expansion, only 38 % presented within 3 h. The accuracy of the spot sign in predicting hematoma expansion was 0.67 for patients presenting within 3 h, 0.83 between 3 and 6 h, 0.88 after 6 h, and 0.76 for patients presenting with an unknown onset time. CONCLUSIONS: A substantial number of patients destined to suffer from hematoma expansion present either late or with an unknown symptom onset time. The CTA spot sign accurately identifies patients destined to expand regardless of time from symptom onset, and may therefore open a path to offer clinical trials and novel therapies to the many patients who do not present acutely.
Authors: Andrew M Demchuk; Dar Dowlatshahi; David Rodriguez-Luna; Carlos A Molina; Yolanda Silva Blas; Imanuel Dzialowski; Adam Kobayashi; Jean-Martin Boulanger; Cheemun Lum; Gord Gubitz; Vasantha Padma; Jayanta Roy; Carlos S Kase; Jayme Kosior; Rohit Bhatia; Sarah Tymchuk; Suresh Subramaniam; David J Gladstone; Michael D Hill; Richard I Aviv Journal: Lancet Neurol Date: 2012-03-08 Impact factor: 44.182
Authors: H Bart Brouwers; Alessandro Biffi; Alison M Ayres; Kristin Schwab; Lynelle Cortellini; Javier M Romero; Natalia S Rost; Anand Viswanathan; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein Journal: Stroke Date: 2012-04-24 Impact factor: 7.914
Authors: C Delcourt; Y Huang; J Wang; E Heeley; R Lindley; C Stapf; C Tzourio; H Arima; M Parsons; J Sun; B Neal; J Chalmers; C Anderson Journal: Int J Stroke Date: 2010-04 Impact factor: 5.266
Authors: Charlotte Jj van Asch; Merel Ja Luitse; Gabriël Je Rinkel; Ingeborg van der Tweel; Ale Algra; Catharina Jm Klijn Journal: Lancet Neurol Date: 2010-01-05 Impact factor: 44.182
Authors: Andrea Morotti; Chia-Ling Phuah; Christopher D Anderson; Michael J Jessel; Kristin Schwab; Alison M Ayres; Alessandro Pezzini; Alessandro Padovani; M Edip Gurol; Anand Viswanathan; Steven M Greenberg; Joshua N Goldstein; Jonathan Rosand Journal: Stroke Date: 2016-04-21 Impact factor: 7.914
Authors: Andrea Morotti; Michael J Jessel; H Bart Brouwers; Guido J Falcone; Kristin Schwab; Alison M Ayres; Anastasia Vashkevich; Christopher D Anderson; Anand Viswanathan; Steven M Greenberg; M Edip Gurol; Javier M Romero; Jonathan Rosand; Joshua N Goldstein Journal: Neurocrit Care Date: 2016-08 Impact factor: 3.210
Authors: Andrea Morotti; H Bart Brouwers; Javier M Romero; Michael J Jessel; Anastasia Vashkevich; Kristin Schwab; Mohammad Rauf Afzal; Christy Cassarly; Steven M Greenberg; Renee Hebert Martin; Adnan I Qureshi; Jonathan Rosand; Joshua N Goldstein Journal: JAMA Neurol Date: 2017-08-01 Impact factor: 18.302
Authors: Katja E Wartenberg; Xia Wang; Paula Muñoz-Venturelli; Alejandro A Rabinstein; Pablo M Lavados; Craig S Anderson; Thompson Robinson Journal: Neurocrit Care Date: 2017-06 Impact factor: 3.210
Authors: David Rodriguez-Luna; Pilar Coscojuela; Marta Rubiera; Michael D Hill; Dar Dowlatshahi; Richard I Aviv; Yolanda Silva; Imanuel Dzialowski; Cheemun Lum; Anna Czlonkowska; Jean-Martin Boulanger; Carlos S Kase; Gord Gubitz; Rohit Bhatia; Vasantha Padma; Jayanta Roy; Alejandro Tomasello; Andrew M Demchuk; Carlos A Molina Journal: Neurology Date: 2016-06-24 Impact factor: 9.910
Authors: H Bart Brouwers; Yuchiao Chang; Guido J Falcone; Xuemei Cai; Alison M Ayres; Thomas W K Battey; Anastasia Vashkevich; Kristen A McNamara; Valerie Valant; Kristin Schwab; Susannah C Orzell; Linda M Bresette; Steven K Feske; Natalia S Rost; Javier M Romero; Anand Viswanathan; Sherry H-Y Chou; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein Journal: JAMA Neurol Date: 2014-02 Impact factor: 18.302